Sow Yaya, Sow Ousmane, Fall Boubacar, Sine Babacar, Sarr Alioune, Zé Ondo Cyrille, Diao Babacar, Ndoye Alain Khassim, Ba Mamadou
Urology and Andrology Department at Aristide Le Dantec Hospital, Cheikh Anta Diop University, Dakar, Senegal.
Res Rep Urol. 2019 May 7;11:137-142. doi: 10.2147/RRU.S204507. eCollection 2019.
To assess the impact of tumor cytoreduction on cancer outcomes and patient survival in metastatic prostate cancer. It is a prospective study spanning a two-year period between October 1st 2015 and March 31st 2017. We enrolled 102 cases of metastatic hormone-sensitive prostate cancer. Fifty-seven (57) patients had exclusively androgen deprivation therapy (ADT) (group 1) and 45 had, in addition, an open prostatectomy or Transurethral resection of the Prostate (group 2). We compared both groups using the total PSA nadir, the time to PSA nadir, the overall survival (OS), and the progression-free survival (PFS). The average nadir PSA was lower for the tumor cytoreduction group (16.8±1.6 ng/mL (0.01-193.5) versus 110.7±17.9 ng/mL (0.01-1379)). Median time to PSA nadir was shorter in patients in the ADT only group (8 months vs 3 months (=0.025)). The OS was shorter in patients treated with ADT only compared to the tumor cytoreduction group (median 14 months vs 24 months, respectively (=0.03)). Similarly, tumor cytoreduction had a positive impact on patient progression (median PFS 20 months (group 1) vs 43 months (group 2)). Tumor cytoreduction has a positive impact on the oncological results and the survival of patients under ADT.
评估肿瘤细胞减灭术对转移性前列腺癌患者癌症结局及生存的影响。这是一项前瞻性研究，为期两年，时间跨度从2015年10月1日至2017年3月31日。我们纳入了102例转移性激素敏感性前列腺癌患者。57例患者仅接受雄激素剥夺治疗（ADT）（第1组），45例患者除接受ADT外，还接受了开放性前列腺切除术或经尿道前列腺切除术（第2组）。我们使用总PSA最低点、达到PSA最低点的时间、总生存期（OS）和无进展生存期（PFS）对两组进行比较。肿瘤细胞减灭术组的平均PSA最低点较低（16.8±1.6 ng/mL（0.01 - 193.5），而另一组为110.7±17.9 ng/mL（0.01 - 1379））。仅接受ADT治疗的患者达到PSA最低点的中位时间较短（8个月对3个月（P = 0.025））。与肿瘤细胞减灭术组相比，仅接受ADT治疗的患者OS较短（中位生存期分别为14个月对24个月（P = 0.03））。同样，肿瘤细胞减灭术对患者的疾病进展有积极影响（中位PFS：第1组20个月对第2组43个月）。肿瘤细胞减灭术对接受ADT治疗患者的肿瘤学结果和生存有积极影响。
